Feature | July 09, 2013

New Correlation for Increased Mortality Associated with Transcatheter Valve Replacement

July 9, 2013 — Researchers have announced the results of a clinical study that shows a key difference in the patient’s baseline heart size and function following transcatheter valve replacement (TAVR) that may help predict their medical outcomes. Previous work by these researchers showed that even mild paravalvular aortic regurgitation (PAR), detected by echocardiograms performed on these patients, appears to correlate with increased mortality. The current study revealed that certain baseline characteristics found on the echocardiograms could help predict which patients were more likely to have PAR.

“This is an exciting discovery that will help us better stratify patients for closer follow-up care,” said Rebecca Hahn, M.D., FASE, the study’s primary investigator. Hahn and her colleagues analyzed 465 patients from the PARTNER trial, combined with another 1,757 patients to show the association between increased PAR and the significant difference in baseline echo parameters. The patients’ echocardiograms indicated larger ventricular volumes and mass, lower ejection fractions and more regurgitant valvular disease, all of which appear to be harbingers of underlying issues that influenced the patient’s long-term outcome following the procedure.

Researchers on the study, "Differences in Baseline Echo Parameters in Patients with Varying Severity of Paravalvular Regurgitation Following Transcatheter Valve Replacement," included Rebecca Hahn, Susheel Kodali, Mathew Williams, Tom McAndrew and Martin Leon from Columbia University, New York, N.Y.; Pamela S. Douglas from Duke University Medical Center, Durham, N.C.;  Philippe Pibarot from Laval University, Quebec, QC, Canada; William Stewart from the Cleveland Clinic Foundation, Cleveland, Ohio; and Neil Weissman from Medstar Health Research Institute, Washington, D.C.

For more information: www.asecho.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2025 — A major international study published in Atherosclerosis* has found that routinely testing for ...

Home August 20, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 4, 2025 — Marea Therapeutics, Inc., a clinical-stage biotechnology company that develops next-generation medicines ...

Home August 04, 2025
Home
News | Cardiovascular Clinical Studies

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic ...

Home July 22, 2025
Home
News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
Subscribe Now